Randomised clinical trial: Escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 11-12, 2011, Pages 1306-1317

  De Knegt, R J ^a   Bezemer, G ^a   Van Gool, A R ^a,b   Drenth, J P H ^c   Hansen, B E ^a   Droogleever Fortuyn, H A ^c   Weegink, C J ^d   Hengeveld, M W ^a   Janssen, H L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Organization for Mental Health   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN;

ADULT; ARTICLE; CONCENTRATION LOSS; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEPATITIS C; HOSTILITY; HUMAN; INCIDENCE; INNER TENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MOOD DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; SADNESS; TIME SERIES ANALYSIS; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; ANXIETY DISORDERS; CITALOPRAM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 81355148539     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04867.x     Document Type: Article

References (38)

1. Lauer GM, Walker BD,. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
5. Russo S, Kema IP, Haagsma EB, et al. Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism. Psychosom Med 2005; 67: 773-7.
6. Dusheiko G,. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26: 112S-21S.
7. Reichenberg A, Gorman JM, Dieterich DT,. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005; 19 (Suppl. 3): S174-8.
8. Lieb K, Engelbrecht MA, Gut O, et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur Psychiatry 2006; 21: 204-10.
9. Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105: 45-55.
10. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B,. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354: 131-2.
11. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
12. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942-7.
13. Kraus MR, Schafer A, Schottker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008; 57: 531-6.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 2000, DSM-IV TR. Arlington, USA: American Psychiatric Publishing, 2000.
15. World Health Organisation, ICD Version 2007. Available at:.
16. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 20: 22-33.
17. Montgomery SA, Asberg M,. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
18. Tyrer P, Owen RT, Cicchetti DV,. The brief scale for anxiety: a subdivision of the comprehensive psychopathological rating scale. J Neurol Neurosurg Psychiatry 1984; 47: 970-5.
19. Beck AT, Steer RA, Carbin MG,. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988; 8: 77-100.
20. Derogatis LR, Lipman RS, Covi L,. SCL-90: an outpatient psychiatric rating scale-preliminary report. Psychopharmacol Bull 1973; 9: 13-28.
21. Asnis GM, De la Garza R,. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology and treatment approaches. J Clin Gastroenterol 2006; 40: 322-35.
22. Leutscher PD, Lagging M, Buhl MR, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010; 52: 430-5.
23. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side-effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-51.
24. Kraus MR, Schafer A, Al-Taie O, Scheurlen M,. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005; 12: 96-100.
25. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42: 793-8.
26. Gleason OC, Fucci JC, Yates WR, Philipsen MA,. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C-a pilot study. Dig Dis Sci 2007; 52: 2557-63.
27. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-6.
28. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P,. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007; 103: 83-90.
29. Morasco BJ, Loftis JM, Indest DW, et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics 2010; 51: 401-8.
30. Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007; 25: 1163-74.
31. Martin-Santos R, Diez-Quevedo C, Castellvi P, et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther 2008; 27: 257-65.
32. Wade A, Andersen HF,. The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 2006; 22: 2101-10.
33. Wade A, Lemming OM, Hedegaard KB,. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95-102.
34. Lepola UM, Loft H, Reines EH,. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211-7.
35. Kennedy SH, Andersen HF, Lam RW,. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006; 31: 122-31.
36. Rowan PJ, Al-Jurdi R, Tavakoli-Tabasi S, Kuni ME, Satrom SL, El-Serag HB,. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. J Clin Gastroenterol 2005; 39: 731-6.
37. Lowry D, Coughlan B, McCarthy O, Crowe J,. Investigating health-related quality of life, mood and neuropsychological test performance in a homogeneous cohort of Irish female hepatitis C patients. J Viral Hepat 2010; 17: 352-9.
38. Dieperink E, Samuel B, Thuras P, Willenbring ML,. A prospective study of neuropsychiatric symptoms associated with interferon-α-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104-12.